Page last updated: 2024-09-04

cox 189 and omeprazole

cox 189 has been researched along with omeprazole in 4 studies

Compound Research Comparison

Studies
(cox 189)
Trials
(cox 189)
Recent Studies (post-2010)
(cox 189)
Studies
(omeprazole)
Trials
(omeprazole)
Recent Studies (post-2010) (omeprazole)
16349479,0852,7371,487

Protein Interaction Comparison

ProteinTaxonomycox 189 (IC50)omeprazole (IC50)
Mcl-1Homo sapiens (human)3.1448
cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.28
Potassium-transporting ATPase alpha chain 1Homo sapiens (human)1.45
Cytochrome P450 2C19Homo sapiens (human)2.315
Potassium-transporting ATPase subunit betaHomo sapiens (human)1.45
WD repeat-containing protein 5Homo sapiens (human)1.7
Glutathione S-transferase omega-1Homo sapiens (human)4.6
Histone-lysine N-methyltransferase 2AHomo sapiens (human)1.7
Muscarinic acetylcholine receptorCavia porcellus (domestic guinea pig)3.8

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Langholff, W; Milosavljev, S; Rordorf, C; Scott, G; Shenouda, M; Vinluan Reynolds, C1
Albert, J; Arulmani, U; Bolten, W; Ell, C; Fortun, P; Hawkey, CJ; Hugot, JL; Keuchel, M; Krammer, G; McAlindon, M; Rebuli, R; Schumann, S; Shonde, A; Simon, B; Toth, E; Yu, V1

Reviews

1 review(s) available for cox 189 and omeprazole

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

2 trial(s) available for cox 189 and omeprazole

ArticleYear
Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib.
    Clinical pharmacokinetics, 2004, Volume: 43, Issue:5

    Topics: Adolescent; Adult; Aluminum Hydroxide; Antacids; Area Under Curve; Cross-Over Studies; Cyclooxygenase 2; Diclofenac; Drug Combinations; Enzyme Inhibitors; Female; Humans; Isoenzymes; Magnesium Hydroxide; Male; Membrane Proteins; Middle Aged; Omeprazole; Organic Chemicals; Prostaglandin-Endoperoxide Synthases; Proton Pump Inhibitors

2004
Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2008, Volume: 6, Issue:5

    Topics: Administration, Oral; Adult; Aged; Capsule Endoscopes; Cross-Over Studies; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Humans; Intestinal Mucosa; Intestine, Small; Male; Middle Aged; Naproxen; Omeprazole; Probability; Reference Values; Risk Assessment; Ulcer

2008

Other Studies

1 other study(ies) available for cox 189 and omeprazole

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013